keyword
MENU ▼
Read by QxMD icon Read
search

Polypill

keyword
https://www.readbyqxmd.com/read/28467941/metabolic-surgery-in-a-pill
#1
Alexander D Miras, Carel W le Roux
Bariatric surgery has evolved from a very effective treatment of weight to a treatment of "metabolism" and end-organ damage. Even though surgery was designed with the aim of causing mechanical restriction and calorie malabsorption, mechanistic work in humans and rodents over the last 10 years or so has informed us that this could not be further from the truth. Dietary, pharmacological, and medical device interventions for weight loss and metabolic control have also evolved rapidly only very recently. In this Crosstalk we discuss how close we are to harnessing the clinical efficacy of surgery through a metabolic "polypill...
May 2, 2017: Cell Metabolism
https://www.readbyqxmd.com/read/28448291/the-polypill-in-cardiovascular-prevention-evidence-limitations-and-perspective-position-paper-of-the-european-society-of-hypertension
#2
Antonio Coca, Enrico Agabiti-Rosei, Renata Cifkova, Athanasios J Manolis, Josep Redón, Giuseppe Mancia
: Antihypertensive, lipid lowering, antidiabetic and antiplatelet treatments all substantially reduce the risk of cardiovascular morbid and fatal events. In real life, however, effective implementation of these treatments is rare, and thus their contribution to cardiovascular prevention is much less than it could be, based on research data. This article reviews the pros and cons of cardiovascular prevention by the polypill approach. It is argued that the high prevalence of individuals with a multifactorial risk profile provides a strong rationale for a therapeutic strategy based on the combination in a single tablet of drugs against different risk factors...
April 26, 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/28436727/impact-of-switching-from-different-treatment-regimens-to-a-fixed-dose-combination-pill-polypill-in-patients-with-cardiovascular-disease-or-similarly-high-risk
#3
Melvin Lafeber, Wilko Spiering, Frank Lj Visseren, Diederick E Grobbee, Michiel L Bots, Alice Stanton, Anushka Patel, Dorairaj Prabhakaran, Ruth Webster, Simon Thom, Anthony Rodgers
Aims Cardiovascular fixed-dose combination pills, or polypills, may help address the widespread lack of access and adherence to proven medicines. Initiation of polypill-based care typically entails switching from current separately taken medications. Given the heterogeneity in usual care, there is interest in the impact of polypill treatment across different patterns of prior medication regimen. Methods A total of 2004 participants with established cardiovascular disease or estimated 5-year cardiovascular risk of over 15% were randomised to polypill-based treatment (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg and either atenolol 50 mg or hydrochlorothiazide 12...
January 1, 2017: European Journal of Preventive Cardiology
https://www.readbyqxmd.com/read/28425033/strengths-and-limitations-of-using-the-polypill-in-cardiovascular-prevention
#4
REVIEW
Ambuj Roy, Nitish Naik, K Srinath Reddy
PURPOSE OF REVIEW: Polypill and its role in cardiovascular disease (CVD) prevention has been extensively discussed and debated since the inception of the concept in 2003. This article reviews the subsequent accumulated research in this area. RECENT FINDINGS: Several short and intermediate to long-term studies with different brands of polypills have analysed the impact of polypill in phase II and III trials. The strengths of polypill that have emerged include better adherence, equivalent or better risk factor control and quality of life among polypill users as compared to usual care...
May 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28365096/preventing-bad-and-expensive-things-from-happening-by-taking-the-healthy-living-polypill-everyone-needs-this-medicine
#5
EDITORIAL
Ross Arena, Carl J Lavie
No abstract text is available yet for this article.
March 13, 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/28347977/whatever-happened-to-the-polypill
#6
EDITORIAL
Anthony J Viera
No abstract text is available yet for this article.
March 27, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28341983/-management-of-different-cardiovascular-risk-factors-with-a%C3%A2-combination-tablet-polypill
#7
REVIEW
P Bramlage, W März, D Westermann, B Weisser, J H Wirtz, U Zeymer, P Baumgart, G van Mark, U Laufs, B K Krämer, T Unger
BACKGROUND: The multifactorial origin of cardiovascular diseases has led to polypharmacy in primary and secondary prophylaxis with evidence-based medications, such as statins, antihypertensive drugs and platelet aggregation inhibitors. The number of prescribed drugs correlates inversely to adherence and can lead to treatment failure. Fixed-dose combination drugs (polypills) could increase the medication adherence of patients, reduce risks and prevent cardiovascular events. METHODS: This review is based on publications that were retrieved from Medline (via PubMed) and The Cochrane Library...
March 24, 2017: Herz
https://www.readbyqxmd.com/read/28320637/polypill-based-therapy-a-promising-therapeutic-strategy
#8
EDITORIAL
Fei Luo, Yuan Guo, Ran Peng, Guiyun Ruan, Xiangping Li
No abstract text is available yet for this article.
March 6, 2017: Heart, Lung & Circulation
https://www.readbyqxmd.com/read/28290999/polypills-an-essential-medicine-for-cardiovascular-disease
#9
EDITORIAL
The Lancet
No abstract text is available yet for this article.
March 11, 2017: Lancet
https://www.readbyqxmd.com/read/28290996/putting-polypills-into-practice-challenges-and-lessons-learned
#10
REVIEW
Ruth Webster, Jose M Castellano, Oyere K Onuma
Regulatory approvals for cardiovascular polypills are increasing rapidly across more than 30 countries. The evidence clearly shows polypills improve adherence and cardiovascular disease risk factors for patients with indications for use of polypill components-ie, those with established cardiovascular disease or at high risk. However, the implementation of polypills into clinical practice has many challenges. The clinical trials literature provides insights into the clinical impact of a polypill strategy, including cost-effectiveness, safety of use, substantial improvement in adherence, and better risk factor control than usual care...
March 11, 2017: Lancet
https://www.readbyqxmd.com/read/28290995/uses-of-polypills-for-cardiovascular-disease-and-evidence-to-date
#11
REVIEW
Mark D Huffman, Denis Xavier, Pablo Perel
Polypills have been approved in more than 30 countries, but worldwide experience with and availability of polypills remain limited, unlike fixed-dose combinations in other diseases such as HIV, tuberculosis, and malaria. In this Series review, we aim to propose a guide for the use of polypills in future research and clinical activities and to synthesise contemporary evidence supporting the use of polypills for prevention of atherosclerosis. Polypill uses can be categorised by population and indication, both of which influence the balance between benefits and risks...
March 11, 2017: Lancet
https://www.readbyqxmd.com/read/28286646/primary-prevention-of-cardiovascular-disease-a-review-of-contemporary-guidance-and-literature
#12
REVIEW
Jack Stewart, Gavin Manmathan, Peter Wilkinson
Cardiovascular disease is a significant and ever-growing problem in the United Kingdom, accounting for nearly one-third of all deaths and leading to significant morbidity. It is also of particular and pressing interest as developing countries experience a change in lifestyle which introduces novel risk factors for cardiovascular disease, leading to a boom in cardiovascular disease risk throughout the developing world. The burden of cardiovascular disease can be ameliorated by careful risk reduction and, as such, primary prevention is an important priority for all developers of health policy...
January 2017: JRSM Cardiovascular Disease
https://www.readbyqxmd.com/read/28263370/fixed-dose-combination-therapy-for-the-prevention-of-atherosclerotic-cardiovascular-diseases
#13
REVIEW
Ehete Bahiru, Angharad N de Cates, Matthew Rb Farr, Morag C Jarvis, Mohan Palla, Karen Rees, Shah Ebrahim, Mark D Huffman
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide, yet ASCVD risk factor control and secondary prevention rates remain low. A fixed-dose combination of blood pressure- and cholesterol-lowering and antiplatelet treatments into a single pill, or polypill, has been proposed as one strategy to reduce the global burden of ASCVD. OBJECTIVES: To determine the effect of fixed-dose combination therapy on all-cause mortality, fatal and non-fatal ASCVD events, and adverse events...
March 6, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28166827/the-polypill-approach-an-innovative-strategy-to-improve-cardiovascular-health-in-europe
#14
Valentín Fuster, Francesc Gambús, Aldo Patriciello, Margaretha Hamrin, Diederick E Grobbee
BACKGROUND: Cardiovascular disease (CVD) is a major cause of disability and premature death. Despite European guidelines advocating the use of medical therapies in CVD, many patients still do not achieve the guideline-recommended treatment, which highlights the need for change and innovations in this field. This requirement has been widely recognised by the national ministries of health, several European cardiology societies, and the European Parliament, who support the initiation of strategies to improve and promote cardiovascular health...
February 7, 2017: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28077465/cost-effectiveness-of-the-polypill-versus-risk-assessment-for-prevention-of-cardiovascular-disease
#15
Bart S Ferket, M G Myriam Hunink, Mohammed Khanji, Isha Agarwal, Kirsten E Fleischmann, Steffen E Petersen
OBJECTIVE: There is an international trend towards recommending medication to prevent cardiovascular disease (CVD) in individuals at increasingly lower cardiovascular risk. We assessed the cost-effectiveness of a population approach with a polypill including a statin (simvastatin 20 mg) and three antihypertensive agents (amlodipine 2.5 mg, losartan 25 mg and hydrochlorothiazide 12.5 mg) and periodic risk assessment with different risk thresholds. METHODS: We developed a microsimulation model for lifetime predictions of CVD events, diabetes, and death in 259 146 asymptomatic UK Biobank participants aged 40-69 years...
April 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/27993410/consensus-document-for-the-use-of-the-polypill-in-the-secondary-prevention-of-cardiovascular-disease
#16
José Ramón González-Juanatey, José María Mostaza, José María Lobos, Benjamín Abarca, José Luis Llisterri, Gonzalo Baron-Esquivias, Enrique Galve, Rosa María Lidón, Francisco Xavier Garcia-Moll, Pedro Luis Sánchez, Carmen Suárez, Jesús Millán, Vicente Pallares, José Juan Alemán, Isabel Egocheaga
Cardiovascular disease is a chronic disorder which is usually already at an advanced stage when the first symptoms develop. The fact that the initial clinical presentation can be lethal or highly incapacitating emphasizes the need for primary and secondary prevention. It is estimated that the ratio of patients with good adherence to secondary prevention of cardiovascular disease is low and also decreases gradually over time. The Polypill for secondary prevention of cardiovascular disease is the first fixed-dose combination therapy of salicylic acid, atorvastatin and ramipril approved in Spain...
February 9, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/27972078/economic-evaluation-of-asa-100mg-simvastatin-40mg-and-ramipril-5-10mg-polypill-for-secondary-prevention-of-cardiovascular-events-in-mexico
#17
L Kaskens, A Gracia, M Rodriguez Mendoza, Y Escobar Juárez, G Mendoza Medrano, H Soto Molina
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27938845/polypill-can-its-potential-enhancement-of-efficacy-trigger-new-interest
#18
EDITORIAL
Jennifer Chao, Sameer Bansilal
No abstract text is available yet for this article.
December 2016: Global Heart
https://www.readbyqxmd.com/read/27892721/social-aspects-in-additive-manufacturing-of-pharmaceutical-products
#19
Johanna Lind, Sofia Kälvemark Sporrong, Susanne Kaae, Jukka Rantanen, Natalja Genina
Additive manufacturing (AM) techniques, such as drug printing, represent a new engineering approach that can implement the concept of personalized medicine via on-demand manufacturing of dosage forms with individually adjusted doses. Implementation of AM principles, such as pharmacoprinting, will challenge the entire drug distribution chain and affect the society at different levels. Areas covered: This work summarizes the concept of personalized medicine and gives an overview of possibilities for monitoring patients' health...
December 7, 2016: Expert Opinion on Drug Delivery
https://www.readbyqxmd.com/read/27844139/-cardiovascular-prevention-and-regular-physical-exercise-activity-and-training-as-the-true-polypill
#20
H Löllgen, N Bachl
Guidelines for cardiovascular prevention need to be regularly revised and updated. With respect to physical activity and exercise, many studies with practical relevance have been published in recent years. They are concerned with the evidence of physical activity for prevention of many diseases and the spectrum of indications for applying physical activity for prevention, therapy and rehabilitation. Training recommendations have been developed for the prevention of various diseases according to the FITT rule, which stands for frequency, intensity, time (of session) and type of sports followed by a progression in the amount of training...
December 2016: Herz
keyword
keyword
11650
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"